S&P 500 Futures
(-0.63%) 5 075.50 points
Dow Jones Futures
(-0.55%) 38 468 points
Nasdaq Futures
(-0.96%) 17 495 points
Oil
(0.14%) $82.93
Gas
(0.42%) $1.660
Gold
(0.15%) $2 341.90
Silver
(0.45%) $27.47
Platinum
(-0.14%) $914.50
USD/EUR
(-0.18%) $0.933
USD/NOK
(-0.36%) $10.94
USD/GBP
(-0.40%) $0.799
USD/RUB
(-0.24%) $92.10

Realtime updates for Ultragenyx Pharmaceutical [RARE]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
75.00%
return 1.17%
SELL
40.00%
return 0.66%
Last Updated24 Apr 2024 @ 16:00

-1.84% $ 44.28

BUY 101711 min ago

@ $45.58

Issued: 14 Feb 2024 @ 15:47


Return: -2.84%


Previous signal: Feb 14 - 09:30


Previous signal: Sell


Return: 2.09 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):
Profile picture for Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally...

Stats
Today's Volume 668 677
Average Volume 702 133
Market Cap 3.65B
EPS $0 ( 2024-02-15 )
Next earnings date ( $-1.720 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -5.37
ATR14 $0.0490 (0.11%)
Insider Trading
Date Person Action Amount type
2024-04-18 Crombez Eric Sell 142 Common Stock
2024-04-16 Huizenga Theodore Alan Sell 14 Common Stock
2024-03-11 Kassberg Thomas Richard Sell 11 509 Common Stock
2024-03-07 Fust Matthew K Sell 2 550 Common Stock
2024-03-07 Fust Matthew K Sell 2 145 Common Stock
INSIDER POWER
45.63
Last 99 transactions
Buy: 915 632 | Sell: 371 334

Volume Correlation

Long: -0.12 (neutral)
Short: 0.92 (very strong)
Signal:(62.083) Expect same movement, but be aware

Ultragenyx Pharmaceutical Correlation

10 Most Positive Correlations
GAINL0.862
ITMR0.852
DVCR0.847
AVEO0.845
ISNS0.842
VLYPP0.831
CHMA0.825
OPNT0.825
SUMR0.813
EDUT0.813
10 Most Negative Correlations
SHSP-0.9
BOCH-0.891
XFOR-0.833
GRCL-0.833
ENPH-0.827
RDHL-0.82
THTX-0.819
PTPI-0.805
QTEK-0.801
BLU-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ultragenyx Pharmaceutical Correlation - Currency/Commodity

The country flag -0.77
( moderate negative )
The country flag -0.76
( moderate negative )
The country flag 0.00
( neutral )
The country flag -0.82
( strong negative )
The country flag 0.80
( moderate )
The country flag 0.58
( weak )

Ultragenyx Pharmaceutical Financials

Annual 2023
Revenue: $434.25M
Gross Profit: $389.04M (89.59 %)
EPS: $-8.25
Q4 2023
Revenue: $127.39M
Gross Profit: $115.34M (90.54 %)
EPS: $-1.520
Q3 2023
Revenue: $98.05M
Gross Profit: $87.07M (88.79 %)
EPS: $-2.23
Q2 2023
Revenue: $108.31M
Gross Profit: $98.40M (90.85 %)
EPS: $-2.25

Financial Reports:

No articles found.

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators